MedTrace Logo

Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis

NCT06042647 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2023-11-18

No results posted yet for this study

Summary

The objective of this research is to demonstrate superior anti-inflammatory effects, as demonstrated by a reduction in TNF-a and IL-17A, with tazarotene/halobetasol lotion in patients with mild to moderate plaque type psoriasis as compared to clobetasol propionate 0.05% cream.

Conditions

  • Psoriasis Vulgaris

Interventions

DRUG

0.01% Halobetasol

Drug to be applied at bedtime to designated target psoriasis plaque at bedtime.

DRUG

0.045% Tazarotene

Drug to be applied in combination with 0.01% Halobetasol to the designated psoriasis plaque at bedtime.

DRUG

0.05% Clobetasol Propionate

Drug to be applied to designated psoriatic plaque at bedtime.

Sponsors & Collaborators

  • Dermatology Consulting Services, PLLC

    lead NETWORK

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-07-13
Primary Completion
2023-11-13
Completion
2023-11-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06042647 on ClinicalTrials.gov